PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-184.01%
Both yoy net incomes decline, with TRVN at -35.73%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-9.94%
Both reduce yoy D&A, with TRVN at -33.87%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-368.86%
Negative yoy deferred tax while TRVN stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
368.86%
SBC growth well above TRVN's 23.13%. Michael Burry would flag major dilution risk vs. competitor’s approach.
55.40%
Less working capital growth vs. TRVN's 197.79%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
252.95%
AP growth of 252.95% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-12.95%
Negative yoy usage while TRVN is 119.39%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
200.11%
Well above TRVN's 93.37%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-85.28%
Negative yoy CFO while TRVN is 41.66%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
80.16%
CapEx growth well above TRVN's 66.62%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.16%
Investing outflow well above TRVN's 66.62%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
54.75%
Debt repayment at 50-75% of TRVN's 100.00%. Martin Whitman would worry about partial lag if competitor gains advantage from lower debt burdens.
-0.41%
Negative yoy issuance while TRVN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.